Corden Pharma Supplies Product Using Continuous Manufacturing
Acasti Pharma, a Quebec-based biopharmaceutical company, reports on the first cGMP batches of CaPre, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary continuous manufacturing process developed in partnership with CordenPharma, a contract development and manufacturing organization.
CaPre is a omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis. The process was jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the CordenPharma Chenôve facility in Dijon, France.
This continuous manufacturing process allows for the production of CaPre with an increased throughput and a small equipment footprint. The process is designed to purify the bioactive molecules of the raw krill oil through continuous and consecutive decantations.